A Phase 3 interventional study of VAL489 and VAL489 matching placebo in Pediatric Hypertension With or Without CKD, sponsored by Novartis Pharmaceuticals. Completed at 27 sites in 9 countries. Open to participants aged 1 Year to 5 Years. Per ClinicalTrials.gov, last updated 2017-09-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 83rd largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2012, is one of 53 in phase 3, and was the 120th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 1 Year to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 150th largest by enrollment of the 222 interventional ones that give a count, is one of 11 that started in 2012, is one of 108 in phase 3, and was the 203rd registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria:
Have the ability to provide written ; Have at baseline , a documented diagnosis of hypertension (as defined in the National High Blood Pressure Education Program 2004); MSBP (mean of 3 measurements) must be ≥95th percentile, and ≤25% above the 95th percentile, for age, gender and height, at baseline; CKD patients must be defined as any of the following criteria: Kidney damage for ≥3 months, as defined by structural or functional abnormalities of the kidney, with or without decreased , manifested by one or more of the following features: Abnormalities in the composition of urine, Abnormalities in imaging tests, Abnormalities on kidney , Estimated eGFR \<60 mL/min/1.73m2 for ≥3 months, with or without the other signs of kidney damage described above; Able to swallow the valsartan solution; Body weight must be ≥8 kg and ≤40 kg at baseline; Must be able to safely washout from other antihypertensive therapy (if applicable) Exclusion criteria /SGOT or ALT/SGPT >3 times the upper limit of the reference range; Estimated Glomerular Filtration Rate [eGFR] \<30 mL/min/1.73m² (calculated using Modified Schwartz Formula); Serum potassium >5.3 mmol/L; Uncontrolled diabetes mellitus, as defined by the investigator; Unilateral, bilateral and graft renal artery stenosis; Current diagnosis of heart failure ( Class II-IV); Patients taking any of the following concomitant medications following screening: RAAS blockers other than study drug, Lithium, Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels; Non-steroidal anti-inflammatory drugs (NSAIDS), including selective COX-2 inhibitors, acetylsalicylic acid >3g/day, and non-selective NSAIDs (paracetamol/acetaminophen is permitted); Antidepressant drugs in the class of MAO inhibitors (e.g. phenelzine); Chronic use of stimulant therapy for ADD/ADHD; patients who have coarctation of the aorta with a gradient of ≥30 mmHg; Previous solid organ transplantation except renal transplantation. Renal transplant must have occurred at least 1 year prior to enrollment; Patient must be on stable doses of therapy and deemed clinically stable by the investigator; Patients known to be positive for the (HIV) Other protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
Drug: VAL489 · Drug: VAL489 matching placebo
Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
Drug: VAL489 · Drug: VAL489 matching placebo
Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
Drug: VAL489
Valsartan 3mg/kg oral solution
Also known as: Diovan
Valsartan 3 mg/kg oral solution
Also known as: Diovan
Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint
Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) at Baseline and Week 6 endpoint in Period 1 Double Blind Phase
Time frame: Baseline, week 6
Change From Baseline in Mean Diastolic Blood Pressure (MDBP) at Week 6
Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Baseline and Week 6 endpoint in Period 1 Double Blind Phase
Time frame: Baseline, Week 6
Patients Achieving <90th Percentile for Age, Gender and Height at Week 6 Endpoint in Both MSBP and MDBP
Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Week 6
Time frame: Week 6
CKD Patients Achieving Urine Albumin Creatinine Ratio Percentage Reduction (UACR) >=25% at Week 6
UACR response is defined as percentage change from baseline in UACR≤ 25%. UACR \[mg/mmol\] = urine albumin \[mg/L\] / urine creatinine \[mmol/L\] UACR was collected for CKD patients only. The UACR value at a given visit for a patient was to be derived by the median of the three lab values collected for that visit Week 6.
Time frame: Week 6 weeks
Overall, 156 patients were screened, of which 127 patients were enrolled in the double blind period 1 of the study. A total of 120 patients (94.5%) completed Period 1 and entered Open Label Period 2.
| Milestone | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg | Valsartan 1 mg/kg (Period 2) |
|---|---|---|---|---|---|
| Started | 32 | 31 | 33 | 31 | 0 |
| Full analysis set (fas) | 31 | 31 | 33 | 31 | 0 |
| Completed | 29 | 30 | 32 | 29 | 0 |
| Not completed | 3 | 1 | 1 | 2 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 | 0 |
| Milestone | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg | Valsartan 1 mg/kg (Period 2) |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 120 |
| Completed | 0 | 0 | 0 | 0 | 114 |
| Not completed | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 |
Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) at Baseline and Week 6 endpoint in Period 1 Double Blind Phase
| mmHg | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg |
|---|---|---|---|---|
| Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint | -1.2 ± 2.05 | -9.2 ± 2.05 | -6.9 ± 1.44 | -7.8 ± 1.48 |
Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Baseline and Week 6 endpoint in Period 1 Double Blind Phase
| mmHg | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg |
|---|---|---|---|---|
| Change From Baseline in Mean Diastolic Blood Pressure (MDBP) at Week 6 | 1.3 ± 1.79 | -6.5 ± 1.79 | -1.9 ± 1.26 | -7.2 ± 1.30 |
Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) Week 6
| participants | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg |
|---|---|---|---|---|
| Patients Achieving <90th Percentile for Age, Gender and Height at Week 6 Endpoint in Both MSBP and MDBP | 6 | 9 | 7 | 8 |
UACR response is defined as percentage change from baseline in UACR≤ 25%. UACR \[mg/mmol\] = urine albumin \[mg/L\] / urine creatinine \[mmol/L\] UACR was collected for CKD patients only. The UACR value at a given visit for a patient was to be derived by the median of the three lab values collected for that visit Week 6.
| participants | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg |
|---|---|---|
| CKD Patients Achieving Urine Albumin Creatinine Ratio Percentage Reduction (UACR) >=25% at Week 6 | 12 | 9 |
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan 0.25 mg/kg | 0/64 (0%) | 2/64 (3.1%) | 19/64 (29.7%) |
| Valsartan 4.0 mg/kg | 0/62 (0%) | 2/62 (3.2%) | 13/62 (21%) |
| All Open Label Patients | 0/120 (0%) | 6/120 (5%) | 62/120 (51.7%) |
| Event | Valsartan 0.25 mg/kg | Valsartan 4.0 mg/kg | All Open Label Patients |
|---|---|---|---|
| GastroenteritisInfections and infestations | 0/64 | 0/62 | 2/120 |
| GastritisGastrointestinal disorders | 0/64 | 1/62 | 0/120 |
| BronchitisInfections and infestations | 1/64 | 1/62 | 0/120 |
| AggressionPsychiatric disorders | 1/64 | 0/62 | 0/120 |
| Oedema peripheralGeneral disorders | 0/64 | 0/62 | 1/120 |
| MastoiditisInfections and infestations | 0/64 | 0/62 | 1/120 |
| PharyngitisInfections and infestations | 0/64 | 0/62 | 1/120 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/64 | 0/62 | 1/120 |
| Nephrotic syndromeRenal and urinary disorders | 0/64 | 0/62 | 1/120 |
| Event | Valsartan 0.25 mg/kg | Valsartan 4.0 mg/kg | All Open Label Patients |
|---|---|---|---|
| PyrexiaGeneral disorders | 2/64 | 3/62 | 20/120 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/64 | 1/62 | 11/120 |
| DiarrhoeaGastrointestinal disorders | 4/64 | 2/62 | 10/120 |
| Upper respiratory tract infectionInfections and infestations | 1/64 | 0/62 | 10/120 |
| VomitingGastrointestinal disorders | 3/64 | 1/62 | 9/120 |
| NasopharyngitisInfections and infestations | 3/64 | 2/62 | 9/120 |
| TonsillitisInfections and infestations | 0/64 | 2/62 | 8/120 |
| Respiratory tract infectionInfections and infestations | 4/64 | 3/62 | 6/120 |
| BronchitisInfections and infestations | 3/64 | 0/62 | 7/120 |
| Ear infectionInfections and infestations | 0/64 | 0/62 | 7/120 |
| Age, Continuous(years) | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 2.99 ± 1.47 | 2.72 ± 1.33 | 3.7 ± 1.51 | 3.62 ± 1.36 | 3.26 ± 1.466 |
| Sex: Female, Male(Participants) | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg | Total |
|---|---|---|---|---|---|
| Female | 12 | 8 | 14 | 13 | 47 |
| Male | 20 | 23 | 19 | 18 | 80 |
| Ethnicity (NIH/OMB)(Participants) | CKD Patients Valsartan 0.25 mg/kg | CKD Patients Valsartan 4 mg/kg | Non-CKD Patients Valsartan 0.25 mg/kg | Non-CKD Patients Valsartan 4 mg/kg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 16 | 14 | 15 | 57 |
| Not Hispanic or Latino | 20 | 15 | 19 | 16 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Nov 2012 to primary completion in Jan 2017, 50 months.
Results were first posted in Sep 2017, 8 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 50 months is above that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valsartan